FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS ...Middle East

Accelerated approval marks a scientific advancement in treatment of superoxide dismutase 1 (SOD1)-amyotrophic lateral sclerosis (ALS) Approval based on reduction of neurofilament, a biomarker associated with neuronal damage in ALS QALSODY joins SPINRAZA® as Ionis-discovered medicine...

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS )

Also on site :

• LEGO Transforms Legendary Rock Band Into Custom Set
• Bryan Kohberger to plead guilty in Idaho killings to avoid execution
• One dead and two injured after stabbing attack at German company